Synergistic Opioid Overdose Rescue Systems

Integrating opioid antagonist delivery with AI, IoT, blockchain, and novel materials to create more effective and personalized opioid overdose rescue systems

The original patent addressed the need for effective opioid overdose rescue, but its limitations include lack of personalized detection, delayed response, and limited therapeutic efficacy. The new inventive concept addresses these limitations by combining opioid antagonist delivery with advanced technologies to provide real-time detection, rapid response, and enhanced therapeutic outcomes

The new inventive concept comprises a system for opioid overdose rescue, integrating an opioid antagonist delivery device with an AI-powered sensor for detecting opioid exposure. The sensor triggers the delivery device to administer a therapeutically effective amount of the opioid antagonist. Additionally, the system may include a blockchain-based reward system to incentivize subjects to maintain abstinence from opioids, or a nanocarrier-based delivery system for targeted opioid receptor binding. The system may also incorporate an IoT-enabled tracking device for monitoring vital signs and an AI-powered predictive model for predicting opioid overdose risk

The new claims introduce the concept of integrating opioid antagonist delivery with AI, IoT, blockchain, and novel materials, which is not obvious from the original patent. The inventive step lies in the synergistic combination of these technologies to create a more effective and personalized opioid overdose rescue system

Alternative embodiments may include using different AI algorithms, varying the type of IoT-enabled tracking device, or incorporating additional novel materials for enhanced therapeutic efficacy. Variations may also include adapting the system for use in different settings, such as emergency response or clinical treatment

The inventive concept has significant commercial potential in the opioid overdose rescue market, with potential applications in emergency response, clinical treatment, and public health initiatives. The target industries include pharmaceutical companies, medical device manufacturers, and healthcare providers